Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,180 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00710528 | Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 192 | Gilead SciencesINDUSTRY | 1 | Aug 31, 2012 | clinicaltrials |
| NCT00793650 | Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study | terminated | Phase 1 / Phase 2 | 39 | Emory UniversityOTHER | 1 | Aug 30, 2012 | clinicaltrials |
| NCT00303199 | Study of ZIO-101 in Multiple Myeloma | completed | Phase 1 / Phase 2 | 35 | Alaunos TherapeuticsINDUSTRY | 2 | Jul 19, 2012 | clinicaltrials |
| NCT00592046 | A Phase I Trial of ZIO-101 in Hematologic Cancers | completed | Phase 1 | 12 | Alaunos TherapeuticsINDUSTRY | 1 | Jul 19, 2012 | clinicaltrials |
| NCT00415064 | Phase I Study of Perifosine + Lenalidomide and Dexamethasone for Patients With Multiple Myeloma | completed | Phase 1 | 32 | AEterna ZentarisINDUSTRY | 1 | Jul 6, 2012 | clinicaltrials |
| NCT00660166 | Human Leukocyte Antigen (HLA) Class I Haplotype Mismatched Natural Killer Cell Infusions | completed | Phase 1 | 13 | Tufts Medical CenterOTHER | 1 | Jun 27, 2012 | clinicaltrials |
| NCT01010243 | Third-line Therapy of Multiple Myeloma a Prospective Phase I /II Trial(MM03) | unknown | Phase 1 / Phase 2 | 54 | University of RegensburgOTHER | 1 | May 30, 2012 | clinicaltrials |
| NCT00234169 | A Study of Peripheral Blood Progenitor Cells Mobilisation (PBPC) With VTP195183 Plus Granulocyte-Colony Stimulating Factor (G-CSF) Compared to Mobilisation With G-CSF Alone | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 10, 2012 | clinicaltrials |
| NCT00089453 | Study of KIR-Ligand Mismatched Haplo-Identical Natural Killer Cells Transfused Before Autologous Stem Cell Transplant | completed | Phase 1 | 10 | University of ArkansasOTHER | 1 | Apr 19, 2012 | clinicaltrials |
| NCT01452334 | Safety Study of Anti-Programmed Death-Ligand 1 in Hematologic Malignancy | withdrawn | Phase 1 | 0 | Bristol-Myers SquibbINDUSTRY | 0 | Feb 23, 2012 | clinicaltrials |
| NCT00608907 | An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib) | completed | Phase 1 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 30, 2012 | clinicaltrials |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 19, 2011 | clinicaltrials |
| NCT00388999 | Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant | completed | Phase 1 | 46 | Enzon Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 5, 2011 | clinicaltrials |
| NCT00281476 | The Effect of High Dose Simvastatine on Multiple Myeloma | completed | Phase 1 / Phase 2 | 10 | Vejle HospitalOTHER | 0 | Nov 1, 2011 | clinicaltrials |
| NCT00562224 | Study of the Safety and Tolerability of Oral Capsule Form of PCI-24781 in Advanced Cancer Patients | completed | Phase 1 | 36 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 28, 2011 | clinicaltrials |
| NCT01221103 | Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL) | unknown | Phase 1 / Phase 2 | 50 | Southern Europe New Drug OrganizationOTHER | 1 | Sep 13, 2011 | clinicaltrials |
| NCT00431990 | A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma | unknown | Phase 1 / Phase 2 | 40 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT01002703 | Treatment With Lenalidomide, Bendamustine and Prednisone (RBP) in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 50 | University of LeipzigOTHER | 1 | Aug 12, 2011 | clinicaltrials |
| NCT00273936 | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies | completed | Phase 1 | 72 | Vertex Pharmaceuticals IncorporatedINDUSTRY | 1 | Aug 4, 2011 | clinicaltrials |
| NCT00891280 | Dose-escalation Study of Oral CX-4945 | unknown | Phase 1 | 55 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01199718 | Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 | 22 | Cylene PharmaceuticalsINDUSTRY | 1 | Jun 15, 2011 | clinicaltrials |
| NCT01010880 | Safety Study of a Chemokine Receptor (CXCR4) Antagonist in Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 16 | Biokine Therapeutics LtdINDUSTRY | 1 | Jun 10, 2011 | clinicaltrials |
| NCT00752518 | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 35 | Janssen Pharmaceutical K.K.INDUSTRY | 0 | May 17, 2011 | clinicaltrials |
| NCT00621400 | Lenalidomide in Combination With Melphalan and Dexamethasone in Newly-diagnosed Light-chain (AL)-Amyloidosis | completed | Phase 1 / Phase 2 | 27 | Nantes University HospitalOTHER | 1 | May 10, 2011 | clinicaltrials |
| NCT01322776 | Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Mar 25, 2011 | clinicaltrials |
| NCT01296204 | Radioimmunotherapy (RIT) in MULTIPLE MYELOMA Using the Antibody B-B4 Radiolabelled With IODE 131(BB4) | completed | Phase 1 | 33 | Centre René GauducheauOTHER | 1 | Mar 22, 2011 | clinicaltrials |
| NCT01170052 | Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL) | withdrawn | Phase 1 / Phase 2 | 20 | Charite University, Berlin, GermanyOTHER | 1 | Mar 16, 2011 | clinicaltrials |
| NCT00050687 | Safety and Pharmacokinetics of Orally Administered Gallium Maltolate in Various Refractory Malignancies | terminated | Phase 1 / Phase 2 | — | Titan PharmaceuticalsINDUSTRY | 1 | Jan 28, 2011 | clinicaltrials |
| NCT00388635 | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. | completed | Phase 1 / Phase 2 | 60 | PETHEMA FoundationOTHER | 1 | Jan 11, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT01233895 | Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma | completed | Phase 1 | 26 | SanofiINDUSTRY | 2 | Nov 3, 2010 | clinicaltrials |
| NCT00935597 | Host Dendritic Cells in Allograft Patients | unknown | Phase 1 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 29, 2010 | clinicaltrials |
| NCT00689000 | Safety and Anti-Disease Activity of CHR-2797 (Tosedostat) in Elderly and/or Treatment Refractory Patients With Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 57 | Chroma TherapeuticsINDUSTRY | 1 | Oct 22, 2010 | clinicaltrials |
| NCT00083460 | Study of Combination PS-341 and Thalidomide in Multiple Myeloma | completed | Phase 1 | 86 | University of ArkansasOTHER | 1 | Aug 2, 2010 | clinicaltrials |
| NCT00081757 | An Open Protocol for the Compassionate Use of Thalidomide | completed | Phase 1 / Phase 2 | 250 | University of ArkansasOTHER | 1 | Jul 2, 2010 | clinicaltrials |
| NCT00459069 | The Use of Dendritic Cell/Tumor Fusions as a Novel Tumor Vaccine in Patients With Multiple Myeloma | completed | Phase 1 | 18 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 12, 2010 | clinicaltrials |
| NCT00243763 | TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma | terminated | Phase 1 | 64 | NovartisINDUSTRY | 1 | Nov 23, 2009 | clinicaltrials |
| NCT00988312 | Dendritic Cells(DC)-Based Id Vaccination in Stage-I Myeloma | completed | Phase 1 | 9 | University Hospital Carl Gustav CarusOTHER | 1 | Oct 2, 2009 | clinicaltrials |
| NCT00425347 | Phase I, Multi-Center, Open-Label, Dose Escalation Study of HuLuc63 in Subjects With Advanced Multiple Myeloma | completed | Phase 1 | 35 | Facet BiotechINDUSTRY | 1 | Sep 23, 2009 | clinicaltrials |
| NCT00186316 | Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells | completed | Phase 1 / Phase 2 | 30 | Stanford UniversityOTHER | 1 | Aug 25, 2009 | clinicaltrials |
| NCT00327249 | Safety and Efficacy Study of Imexon for Treatment of Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | — | AmpliMed CorporationINDUSTRY | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00306813 | Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 53 | University of WuerzburgOTHER | 1 | Aug 4, 2009 | clinicaltrials |
| NCT00547404 | Phase I Study for Safety and Efficacy of P276-00 in Subjects With Myeloma | withdrawn | Phase 1 | 35 | Piramal Enterprises LimitedINDUSTRY | 0 | Apr 23, 2009 | clinicaltrials |
| NCT00080405 | Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma | completed | Phase 1 | 40 | Millennium Pharmaceuticals, Inc.INDUSTRY | 0 | Mar 27, 2009 | clinicaltrials |
| NCT00291538 | Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma | completed | Phase 1 | 20 | Nantes University HospitalOTHER | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00039754 | A Trial of Skeletal Targeted Radiotherapy Using Holmium-166-DOTMP in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | — | Poniard PharmaceuticalsINDUSTRY | 0 | Jan 21, 2009 | clinicaltrials |
| NCT00821301 | Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma | unknown | Phase 1 | 30 | Immune ControlINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00352742 | A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | AttenuonINDUSTRY | 1 | Oct 28, 2008 | clinicaltrials |
| NCT00290004 | Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | completed | Phase 1 / Phase 2 | 35 | Pharmacyclics LLC.INDUSTRY | 1 | Sep 11, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 31, 2012source: clinicaltrials